Bill Detail
H.R. 1672
Congress: 119
Title
Maintaining Investments in New Innovation Act
Summary
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Sponsor
Rep. Donald Davis [D-NC-1]
Status
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Status as of Aug 4, 2:44 AM · synced 9d ago
Introduced
2025-02-27
Data source mode: congress-gov
Bill Engagement
Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to…
Lobbyists on the case
- Biotechnology Innovation Organization5 filings · 15 lobs
- Phyllis Arthur2026 Q1
- Elisabeth Fox2026 Q1
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.